200,000+ products from a single source!

sales@angenechem.com

Home > Carboxes > 157434-99-6

157434-99-6

157434-99-6 | Propanoic acid, 2-[4-[(7-chloro-2-quinoxalinyl)oxy]phenoxy]-, sodium salt (1:1)

CAS No: 157434-99-6 Catalog No: AG001PGF MDL No:

Product Description

Catalog Number:
AG001PGF
Chemical Name:
Propanoic acid, 2-[4-[(7-chloro-2-quinoxalinyl)oxy]phenoxy]-, sodium salt (1:1)
CAS Number:
157434-99-6
Molecular Formula:
C17H12ClN2NaO4
Molecular Weight:
366.7310
IUPAC Name:
sodium;2-[4-(7-chloroquinoxalin-2-yl)oxyphenoxy]propanoate
InChI:
InChI=1S/C17H13ClN2O4.Na/c1-10(17(21)22)23-12-3-5-13(6-4-12)24-16-9-19-14-7-2-11(18)8-15(14)20-16;/h2-10H,1H3,(H,21,22);/q;+1/p-1
InChI Key:
OJENKXNXJPNEPU-UHFFFAOYSA-M
SMILES:
CC(C(=O)[O-])Oc1ccc(cc1)Oc1cnc2c(n1)cc(cc2)Cl.[Na+]

Properties

Complexity:
437  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
2  
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
366.038g/mol
Formal Charge:
0
Heavy Atom Count:
25  
Hydrogen Bond Acceptor Count:
6  
Hydrogen Bond Donor Count:
0
Isotope Atom Count:
0
Molecular Weight:
366.733g/mol
Monoisotopic Mass:
366.038g/mol
Rotatable Bond Count:
5  
Topological Polar Surface Area:
84.4A^2
Undefined Atom Stereocenter Count:
1  
Undefined Bond Stereocenter Count:
0

Literature

Title Journal
R(+)XK469 inhibits hydroxylation of S-warfarin by CYP2C9. European journal of cancer (Oxford, England : 1990) 20090701
The chemotherapeutic agents XK469 (2-{4-[(7-chloro-2-quinoxalinyl)oxy]phenoxy}propionic acid) and SH80 (2-{4-[(7-bromo-2-quinolinyl)oxy]phenoxy}propionic acid) inhibit cytokinesis and promote polyploidy and induce senescence. The Journal of pharmacology and experimental therapeutics 20090301
[Mechanisms of G2/M cycle arrest induced by topo IIalpha and II beta inhibitors in H460 cells]. Nan fang yi ke da xue xue bao = Journal of Southern Medical University 20081201
A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia. Investigational new drugs 20080801
A phase I and pharmacokinetic study of the quinoxaline antitumour Agent R(+)XK469 in patients with advanced solid tumours. European journal of cancer (Oxford, England : 1990) 20080801
Ethonafide-induced cytotoxicity is mediated by topoisomerase II inhibition in prostate cancer cells. The Journal of pharmacology and experimental therapeutics 20070601
A phase 1 trial of XK469: toxicity profile of a selective topoisomerase IIbeta inhibitor. Investigational new drugs 20070401
The role of autophagy in the death of L1210 leukemia cells initiated by the new antitumor agents, XK469 and SH80. Molecular cancer therapeutics 20070101
Synthesis and biological evaluation of conformationally constrained analogs of the antitumor agents XK469 and SH80. Part 5. Bioorganic & medicinal chemistry 20060401
Solubilization of two structurally related anticancer drugs: XK-469 and PPA. Journal of pharmaceutical sciences 20060101
Metabolic profile of XK469 (2(R)-[4-(7-chloro-2-quinoxalinyl)oxyphenoxy]-propionic acid; NSC698215) in patients and in vitro: low potential for active or toxic metabolites or for drug-drug interactions. Cancer chemotherapy and pharmacology 20051001
Synthetic modification of the 2-oxypropionic acid moiety in 2-{4-[(7-chloro-2-quinoxalinyl)oxy]phenoxy}propionic acid (XK469), and consequent antitumor effects. Part 4. Bioorganic & medicinal chemistry 20050602
[Effect of XK469 and adriamycin on the growth of H460 cells in vitro and its mechanism]. Di 1 jun yi da xue xue bao = Academic journal of the first medical college of PLA 20040701
XK469, a topo IIbeta inhibitor, induces apoptosis in Waldenstrom's macroglobulinemia through multiple pathways. International journal of oncology 20031201
Preclinical evaluation of 2-[4-(7-chloro-2-quinoxalinyloxy)phenoxy]-propionic acid as a modulator of etoposide in human Waldenstrom's macroglobulinemia xenograft model. Clinical cancer research : an official journal of the American Association for Cancer Research 20031115
DNA sequence specificity for topoisomerase II poisoning by the quinoxaline anticancer drugs XK469 and CQS. Molecular pharmacology 20030601
2-[4-(7-chloro-2-quinoxalinyloxy)phenoxy]-propionic acid (XK469) inhibition of topoisomerase IIbeta is not sufficient for therapeutic response in human Waldenstrom's macroglobulinemia xenograft model. Molecular cancer therapeutics 20021201
2-[4-(7-chloro-2-quinoxalinyloxyphenoxy]-propionic acid (XK469), an inhibitor of topoisomerase (Topo) IIbeta, up-regulates Topo IIalpha and enhances Topo IIalpha-mediated cytotoxicity. Molecular cancer therapeutics 20021201
Induction of apoptosis by the new anticancer drug XK469 in human ovarian cancer cell lines. Oncogene 20020704
II. Synthesis and biological evaluation of some bioisosteres and congeners of the antitumor agent, 2-(4-[(7-chloro-2-quinoxalinyl)oxy]phenoxy)propionic acid (XK469). Journal of medicinal chemistry 20020704
Preclinical efficacy evaluations of XK-469: dose schedule, route and cross-resistance behavior in tumor bearing mice. Investigational new drugs 20020201
Mitotic arrest induced by XK469, a novel antitumor agent, is correlated with the inhibition of cyclin B1 ubiquitination. International journal of cancer 20020101
Cellular drug action profile paradigm applied to XK469. Journal of experimental therapeutics & oncology 20020101
The investigational new drug XK469 induces G(2)-M cell cycle arrest by p53-dependent and -independent pathways. Clinical cancer research : an official journal of the American Association for Cancer Research 20011101
Pro-apoptotic interactions between XK469 and the peripheral benzodiazepine receptor. Cancer letters 20010726
Design, synthesis, and biological evaluation of analogues of the antitumor agent, 2-(4-[(7-chloro-2-quinoxalinyl)oxy]phenoxy)propionic acid (XK469). Journal of medicinal chemistry 20010524

© 2019 Angene International Limited. All rights Reserved.